Cargando…
RIP1/RIP3-regulated necroptosis as a target for multifaceted disease therapy (Review)
Necroptosis is a type of programmed cell death with necrotic morphology, occurring in a variety of biological processes, including inflammation, immune response, embryonic development and metabolic abnormalities. The current nomenclature defines necroptosis as cell death mediated by signal transduct...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
D.A. Spandidos
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6658002/ https://www.ncbi.nlm.nih.gov/pubmed/31198981 http://dx.doi.org/10.3892/ijmm.2019.4244 |
_version_ | 1783438891473174528 |
---|---|
author | Liu, Yuping Liu, Ting Lei, Tiantian Zhang, Dingding Du, Suya Girani, Lea Qi, Dandan Lin, Chen Tong, Rongsheng Wang, Yi |
author_facet | Liu, Yuping Liu, Ting Lei, Tiantian Zhang, Dingding Du, Suya Girani, Lea Qi, Dandan Lin, Chen Tong, Rongsheng Wang, Yi |
author_sort | Liu, Yuping |
collection | PubMed |
description | Necroptosis is a type of programmed cell death with necrotic morphology, occurring in a variety of biological processes, including inflammation, immune response, embryonic development and metabolic abnormalities. The current nomenclature defines necroptosis as cell death mediated by signal transduction from receptor-interacting serine/threonine kinase (RIP) 1 to RIP3 (hereafter called RIP1/RIP3). However, RIP3-dependent cell death would be a more precise definition of necroptosis. RIP3 is indispensable for necroptosis, while RIP1 is not consistently involved in the signal transduction. Notably, deletion of RIP1 even promotes RIP3-mediated necroptosis under certain conditions. Necroptosis was previously thought as an alternate process of cell death in case of apoptosis inhibition. Currently, necroptosis is recognized to serve a pivotal role in regulating various physiological processes. Of note, it mediates a variety of human diseases, such as ischemic brain injury, immune system disorders and cancer. Targeting and inhibiting necroptosis, therefore, has the potential to be used for therapeutic purposes. To date, research has elucidated the suppression of RIP1/RIP3 via effective inhibitors and highlighted their potential application in disease therapy. The present review focused on the molecular mechanisms of RIP1/RIP3-mediated necroptosis, explored the functions of RIP1/RIP3 in necroptosis, discussed their potential as a novel therapeutic target for disease therapy, and provided valuable suggestions for further study in this field. |
format | Online Article Text |
id | pubmed-6658002 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | D.A. Spandidos |
record_format | MEDLINE/PubMed |
spelling | pubmed-66580022019-08-07 RIP1/RIP3-regulated necroptosis as a target for multifaceted disease therapy (Review) Liu, Yuping Liu, Ting Lei, Tiantian Zhang, Dingding Du, Suya Girani, Lea Qi, Dandan Lin, Chen Tong, Rongsheng Wang, Yi Int J Mol Med Articles Necroptosis is a type of programmed cell death with necrotic morphology, occurring in a variety of biological processes, including inflammation, immune response, embryonic development and metabolic abnormalities. The current nomenclature defines necroptosis as cell death mediated by signal transduction from receptor-interacting serine/threonine kinase (RIP) 1 to RIP3 (hereafter called RIP1/RIP3). However, RIP3-dependent cell death would be a more precise definition of necroptosis. RIP3 is indispensable for necroptosis, while RIP1 is not consistently involved in the signal transduction. Notably, deletion of RIP1 even promotes RIP3-mediated necroptosis under certain conditions. Necroptosis was previously thought as an alternate process of cell death in case of apoptosis inhibition. Currently, necroptosis is recognized to serve a pivotal role in regulating various physiological processes. Of note, it mediates a variety of human diseases, such as ischemic brain injury, immune system disorders and cancer. Targeting and inhibiting necroptosis, therefore, has the potential to be used for therapeutic purposes. To date, research has elucidated the suppression of RIP1/RIP3 via effective inhibitors and highlighted their potential application in disease therapy. The present review focused on the molecular mechanisms of RIP1/RIP3-mediated necroptosis, explored the functions of RIP1/RIP3 in necroptosis, discussed their potential as a novel therapeutic target for disease therapy, and provided valuable suggestions for further study in this field. D.A. Spandidos 2019-09 2019-06-14 /pmc/articles/PMC6658002/ /pubmed/31198981 http://dx.doi.org/10.3892/ijmm.2019.4244 Text en Copyright: © Liu et al. This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License (https://creativecommons.org/licenses/by-nc-nd/4.0/) , which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made. |
spellingShingle | Articles Liu, Yuping Liu, Ting Lei, Tiantian Zhang, Dingding Du, Suya Girani, Lea Qi, Dandan Lin, Chen Tong, Rongsheng Wang, Yi RIP1/RIP3-regulated necroptosis as a target for multifaceted disease therapy (Review) |
title | RIP1/RIP3-regulated necroptosis as a target for multifaceted disease therapy (Review) |
title_full | RIP1/RIP3-regulated necroptosis as a target for multifaceted disease therapy (Review) |
title_fullStr | RIP1/RIP3-regulated necroptosis as a target for multifaceted disease therapy (Review) |
title_full_unstemmed | RIP1/RIP3-regulated necroptosis as a target for multifaceted disease therapy (Review) |
title_short | RIP1/RIP3-regulated necroptosis as a target for multifaceted disease therapy (Review) |
title_sort | rip1/rip3-regulated necroptosis as a target for multifaceted disease therapy (review) |
topic | Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6658002/ https://www.ncbi.nlm.nih.gov/pubmed/31198981 http://dx.doi.org/10.3892/ijmm.2019.4244 |
work_keys_str_mv | AT liuyuping rip1rip3regulatednecroptosisasatargetformultifaceteddiseasetherapyreview AT liuting rip1rip3regulatednecroptosisasatargetformultifaceteddiseasetherapyreview AT leitiantian rip1rip3regulatednecroptosisasatargetformultifaceteddiseasetherapyreview AT zhangdingding rip1rip3regulatednecroptosisasatargetformultifaceteddiseasetherapyreview AT dusuya rip1rip3regulatednecroptosisasatargetformultifaceteddiseasetherapyreview AT giranilea rip1rip3regulatednecroptosisasatargetformultifaceteddiseasetherapyreview AT qidandan rip1rip3regulatednecroptosisasatargetformultifaceteddiseasetherapyreview AT linchen rip1rip3regulatednecroptosisasatargetformultifaceteddiseasetherapyreview AT tongrongsheng rip1rip3regulatednecroptosisasatargetformultifaceteddiseasetherapyreview AT wangyi rip1rip3regulatednecroptosisasatargetformultifaceteddiseasetherapyreview |